Literature DB >> 10481813

Is the societal perspective in cost-effectiveness analysis useful for decision makers?

L B Russell1, D G Fryback, F A Sonnenberg.   

Abstract

BACKGROUND: The U.S. Public Health Service's Panel on Cost-Effectiveness in Health and Medicine recommends that cost-effectiveness analyses (CEAs) intended to help allocate health resources in the public interest include a reference case analysis, conducted from the perspective of society as a whole. This perspective requires that an analysis measure all health effects and changes in resource use caused by an intervention. VALUE OF SOCIETAL CEAs: Tensions unavoidably arise among the parties to medical decisions--patients, their families and friends, clinicians, and third-party payers. One common approach to handling these tensions is to ignore some of them, to "solve" them by pretending they do not or should not exist. Patients do this when they demand the best care for themselves without regard to the cost to others, payers when they make coverage decisions that shift costs ot others. But by estimating all gains and losses, calculations that reflect the safety, effectiveness, and side effects of an intervention as well as its costs, societal CEAs can help resolve those tensions and provide the basis for decisions that are fair to all parties, an agenda for negotiating such decisions, and information essential for designing compensation and incentives to support them. MAKING BETTER USE OF SOCIETAL CEAs: Use of the societal perspective asks that all parties be aware of and consider the interests of others. Some process or procedure needs to be developed for presenting CEA information to the parties most likely to be affected by decisions, soliciting their views, and negotiating an acceptable decision. This process could be used by government decision makers or by managed care organizations, professional societies, or payers.

Entities:  

Mesh:

Year:  1999        PMID: 10481813     DOI: 10.1016/s1070-3241(16)30458-8

Source DB:  PubMed          Journal:  Jt Comm J Qual Improv        ISSN: 1070-3241


  9 in total

1.  Cost effectiveness of endoscopic gallbladder drainage to treat acute cholecystitis in poor surgical candidates.

Authors:  Juan E Corral; Ananya Das; Paul T Krӧner; Victoria Gomez; Michael B Wallace
Journal:  Surg Endosc       Date:  2019-07-26       Impact factor: 4.584

Review 2.  Cost-effectiveness of Colorectal Cancer Screening and Treatment Methods: Mapping of Systematic Reviews.

Authors:  Hossein Mashhadi Abdolahi; Ali Sarabi Asiabar; Saber Azami-Aghdash; Fatemeh Pournaghi-Azar; Aziz Rezapour
Journal:  Asia Pac J Oncol Nurs       Date:  2018 Jan-Mar

Review 3.  Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews.

Authors:  Farbod Ebadifard Azar; Saber Azami-Aghdash; Fatemeh Pournaghi-Azar; Alireza Mazdaki; Aziz Rezapour; Parvin Ebrahimi; Negar Yousefzadeh
Journal:  BMC Health Serv Res       Date:  2017-06-19       Impact factor: 2.655

4.  Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda.

Authors:  Laura Di Giorgio; Mercy Mvundura; Justine Tumusiime; Chloe Morozoff; Jane Cover; Jennifer Kidwell Drake
Journal:  Contraception       Date:  2018-08-09       Impact factor: 3.375

5.  Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.

Authors:  Stavros Simeonidis; Stefania Koutsilieri; Athanassios Vozikis; David N Cooper; Christina Mitropoulou; George P Patrinos
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

6.  Assessing the cost-effectiveness of interventions within a humanitarian organisation.

Authors:  Chloe Puett
Journal:  Disasters       Date:  2019-04-22

7.  The effectiveness of exercise therapy and education plus cognitive behavioral therapy, alone or in combination with total knee arthroplasty in patients with knee osteoarthritis - study protocol for the MultiKnee trial.

Authors:  Maren Falch Lindberg; Arild Aamodt; Mona Badawy; Ingvild B Bergvad; Petter Borchgrevink; Ove Furnes; Caryl Gay; Stig Heir; Inger Holm; Kari Indrekvam; Nina Kise; Bjørn Lau; Jon Magnussen; Tor Kjetil Nerhus; Turid Rognsvåg; Daniil E Rudsengen; Tone Rustøen; Søren T Skou; Jan Stubberud; Milada S Småstuen; Anners Lerdal
Journal:  BMC Musculoskelet Disord       Date:  2021-12-20       Impact factor: 2.362

8.  Economic evaluation of a reduced dosage of ready-to-use therapeutic foods to treat uncomplicated severe acute malnourished children aged 6-59 months in Burkina Faso.

Authors:  Dieynaba S N'Diaye; Bibata Wassonguema; Victor Nikièma; Suvi T Kangas; Cécile Salpéteur
Journal:  Matern Child Nutr       Date:  2021-02-23       Impact factor: 3.092

9.  Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.

Authors:  David D Kim; Madison C Silver; Natalia Kunst; Joshua T Cohen; Daniel A Ollendorf; Peter J Neumann
Journal:  Pharmacoeconomics       Date:  2020-10       Impact factor: 4.981

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.